---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-010538"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T07:11:42.598294+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MolDX publishes Medicare LCD for esophageal cancer testing; effective May 14, 2023

## Summary
- Foundational LCD L39256 provides criteria for future coverage of molecular tests like EsoGuard.
- LCD incorporates stakeholder feedback from 2022 draft, aligning with ACG guidelines and non-endoscopic testing.
- Lucid plans to submit EsoGuard for Technical Assessment later this year after clinical utility data completion.
- Company also highlights recent in-network agreement with MultiPlan to expand commercial payer coverage.
- Lucid is a majority-owned subsidiary of PAVmed Inc. (PAVM).

## SEC filing metadata
- accession: 0001493152-23-010538
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315223010538/0001493152-23-010538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315223010538/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-010538
- JSON: https://secwatch.observer/filing/0001493152-23-010538.json
- Plain text: https://secwatch.observer/filing/0001493152-23-010538.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.